Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Study to Evaluate the Safety and Efficacy of Rocbrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin (R-GemOx) in Patients With Refractory or Relapsed Diffuse Large B-cell Lymphoma

NCT07570017 is registered in ClinicalTrials.gov with Guangzhou Lupeng Pharmaceutical Company LTD. as lead sponsor.

NCT NCT07570017
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07570017 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Study to Evaluate the Safety and Efficacy of Rocbrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin (R-GemOx) in Patients With Refractory or Relapsed Diffuse Large B-cell Lymphoma
Lead sponsor
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase
Phase 1
Overall status
Recruiting
Start date
June 25, 2026
Completion date
July 31, 2028
Enrollment
42 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

dlbcl